Psychedelics clinical and regulatory tailwinds create buyout opportunities
The bull case argued is that favorable regulatory shifts under the Trump administration and strong clinical data positioning psychedelic medicine to replace traditional SSRIs could lead to eventual big pharma acquisitions.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.